In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial)
Saphenous vein grafts (SVGs) have high rates of in-stent restenosis (ISR). We compared the baseline clinical and angiographic characteristics of patients and lesions that did develop ISR with those who did not develop ISR during a median follow-up of 2.7 years in the DIVA study (NCT01121224). We als...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2022
|
| Sorozat: | AMERICAN JOURNAL OF CARDIOLOGY
162 |
| Tárgyszavak: | |
| doi: | 10.1016/j.amjcard.2021.09.024 |
| mtmt: | 32764127 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/24274 |
| LEADER | 02490nab a2200385 i 4500 | ||
|---|---|---|---|
| 001 | publ24274 | ||
| 005 | 20220503104021.0 | ||
| 008 | 220503s2022 hu o 0|| Angol d | ||
| 022 | |a 0002-9149 | ||
| 024 | 7 | |a 10.1016/j.amjcard.2021.09.024 |2 doi | |
| 024 | 7 | |a 32764127 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a Angol | ||
| 100 | 1 | |a Xenogiannis Iosif | |
| 245 | 1 | 0 | |a In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial) |h [elektronikus dokumentum] / |c Xenogiannis Iosif |
| 260 | |c 2022 | ||
| 300 | |a 24-30 | ||
| 490 | 0 | |a AMERICAN JOURNAL OF CARDIOLOGY |v 162 | |
| 520 | 3 | |a Saphenous vein grafts (SVGs) have high rates of in-stent restenosis (ISR). We compared the baseline clinical and angiographic characteristics of patients and lesions that did develop ISR with those who did not develop ISR during a median follow-up of 2.7 years in the DIVA study (NCT01121224). We also examined the ISR types using the Mehran classification. ISR developed in 119 out of the 575 DIVA patients (21%), with similar incidence among patients with drug-eluting stents and bare-metal stents (BMS) (21% vs 21%, p = 0.957). Patients in the ISR group were younger (67 ± 7 vs 69 ± 8 years, p = 0.04) and less likely to have heart failure (27% vs 38%, p = 0.03) and SVG lesions with Thrombolysis In Myocardial Infarction 3 flow before the intervention (77% vs 83%, p <0.01), but had a higher number of target SVG lesions (1.33 ± 0.64 vs 1.16 ± 0.42, p <0.01), more stents implanted in the target SVG lesions (1.52 ± 0.80 vs 1.31 ± 0.66, p <0.01), and longer total stent length (31.37 ± 22.11 vs 25.64 ± 17.42 mm, p = 0.01). The incidence of diffuse ISR was similar in patients who received drug-eluting-stents and BMS (57% vs 54%, p = 0.94), but BMS patients were more likely to develop occlusive restenosis (17% vs 33%, p = 0.05). © 2021 | |
| 650 | 4 | |a Klinikai orvostan | |
| 700 | 0 | 1 | |a Rangan Bavana V. |e aut |
| 700 | 0 | 1 | |a Uyeda Lauren |e aut |
| 700 | 0 | 1 | |a Banerjee Subhash |e aut |
| 700 | 0 | 1 | |a Edson Robert |e aut |
| 700 | 0 | 1 | |a Bhatt Deepak L. |e aut |
| 700 | 0 | 1 | |a Goldman Steven |e aut |
| 700 | 0 | 1 | |a Holmes David R. |e aut |
| 700 | 0 | 1 | |a Rao Sunil V. |e aut |
| 700 | 0 | 1 | |a Shunk Kendrick |e aut |
| 700 | 0 | 1 | |a Mavromatis Kreton |e aut |
| 700 | 0 | 1 | |a Ramanathan Kodangudi |e aut |
| 700 | 0 | 1 | |a Bavry Antony A. |e aut |
| 700 | 0 | 1 | |a McFalls Edward O. |e aut |
| 700 | 0 | 1 | |a Karácsonyi Judit |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/24274/1/Xeno2022.pdf |z Dokumentum-elérés |